Search Results - "Palhagen, S."

Selegiline slows the progression of the symptoms of Parkinson disease by PALHAGEN, S, HEINONEN, E, HÄGGLUND, J, KAUGESAAR, T, MÄKI-IKOLA, O, PALM, R

“…To study the long-term effects of selegiline in monotherapy and in combination with levodopa in the early phase of Parkinson disease (PD). One hundred…”
Get full text

EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease by Martinez-Martin, Pablo, Reddy, Prashanth, Katzenschlager, Regina, Antonini, Angelo, Todorova, Antoniya, Odin, Per, Henriksen, Tove, Martin, Anne, Calandrella, Daniela, Rizos, Alexandra, Bryndum, Narissah, Glad, Arne, Dafsari, Haidar Salimi, Timmermann, Lars, Ebersbach, Georg, Kramberger, Milica G., Samuel, Michael, Wenzel, Karoline, Tomantschger, Volker, Storch, Alexander, Reichmann, Heinz, Pirtosek, Zvezdan, Trost, Maja, Svenningsson, Per, Palhagen, Sven, Volkmann, Jens, Chaudhuri, K. Ray

“…ABSTRACT Subcutaneous apomorphine infusion (Apo) and intrajejunal levodopa infusion (IJLI) are two treatment options for patients with advanced Parkinson's…”
Get full text

Is excessive daytime sleepiness a separate manifestation in Parkinson's disease? by Höglund, A., Broman, J.-E., Pålhagen, S., Fredrikson, S., Hagell, P.

“…Background Excessive daytime sleepiness (EDS) is common in Parkinson's disease (PD), but its role and relation to other PD features is less well understood…”
Get full text

Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease by Pålhagen, S. E., Dizdar, N., Hauge, T., Holmberg, B., Jansson, R., Linder, J., Nyholm, D., Sydow, O., Wainwright, M., Widner, H., Johansson, A.

“…Background This interim 12‐month analysis is a part of an open‐label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa…”
Get full text

Neuropeptide Y and calcitonin gene-related peptide in CSF in Parkinson’s disease with comorbid depression versus major depressive disorder by Mathé, A.A., Pâlhagen, S., Svenningsson, P.

Get full text

Excessive daytime sleepiness in Parkinson's disease: a 10-year longitudinal study by Höglund, A., Broman, J. -E, Hagell, Peter, Palhagen, S., Fredrikson, S.

Get full text

Depressive illness in Parkinson's disease - indication of a more advanced and widespread neurodegenerative process? by Pålhagen, S. E., Carlsson, M., Curman, E., Wålinder, J., Granérus, A.-K.

“…Objective –  The aims were to study if the type and complexity of Parkinsonian symptoms, as well as treatment, could be related to the occurrence and severity…”
Get full text

Associations Between Fluctuations in Daytime Sleepiness and Motor and Non‐Motor Symptoms in Parkinson's Disease by Höglund, Arja, Hagell, Peter, Broman, Jan‐Erik, Pålhagen, Sven, Sorjonen, Kimmo, Fredrikson, Sten, Svenningsson, Per

“…ABSTRACT Background Non‐motor fluctuations are a major concern in Parkinson's disease (PD), and they have been categorized into neuropsychiatric, autonomic and…”
Get full text

Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy by Pålhagen, Sven, Canger, Raffaele, Henriksen, Olaf, van Parys, Johan A., Rivière, Marie-Emmanuelle, Karolchyk, Mary Ann

“…Objective: This was the first proof of principle clinical trial assessing the efficacy and safety of rufinamide as adjunctive therapy in epileptic patients…”
Get full text

Workforce unavailability in Parkinson's disease by Timpka, J., Svensson, J., Nilsson, M. H., Pålhagen, S., Hagell, P., Odin, P.

“…Objectives Individuals with Parkinson's disease (PD) become unavailable in the workforce earlier than comparable members of the general population. This may…”
Get full text

A Swedish version of the 16-item Parkinson fatigue scale (PFS-16) by Hagell, P., Rosblom, T., Pålhagen, S.

“…Hagell P, Rosblom T, Pålhagen S. A Swedish version of the 16‐item Parkinson fatigue scale (PFS‐16). 
Acta Neurol Scand: 2012: 125: 288–292. 
© 2011 John Wiley…”
Get full text

Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding by Červenka, Simon, Pålhagen, Sven E., Comley, Robert A., Panagiotidis, Georgios, Cselényi, Zsolt, Matthews, Julian C., Lai, Robert Y., Halldin, Christer, Farde, Lars

“…Clinical observations support a central role of the dopamine system in restless legs syndrome (RLS) but previous imaging studies of striatal dopamine…”
Get full text

Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease by Westin, J., Nyholm, D., Groth, T., Dougherty, M.S., Yerramsetty, P.K., Palhagen, S.E.

“…Two studies comparing intraduodenal infusion of a levodopa/carbidopa gel with oral treatments in advanced PD patients demonstrated improvement in UPDRS scores…”
Get full text

Factors of importance for weight loss in elderly patients with Parkinson's disease by Lorefält, B., Ganowiak, W., Pålhagen, S., Toss, G., Unosson, M., Granérus, A.-K.

“…Objective –  Weight loss is reported frequently in patients with Parkinson's disease (PD). The objective of this study was to find the underlying factors of…”
Get full text

Study of Intracerebroventricular Administration of SNN0031 (rhPDGF-BB) to Patients with Parkinson's Disease (PD), Using an Implanted Pump System by Gerdhem, Paul, Widner, Håkan, Palhagen, S., Rehncrona, Stig, Lind, G., Linderoth, B., Bjartmarz, Hjalmar, Jansson, K., Herne, N., Zachrisson, O., Haegerstrand, A., Almqvist, P.

Get full text

Does l-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease? by Pålhagen, S., Lorefält, B., Carlsson, M., Ganowiak, W., Toss, G., Unosson, M., Granérus, A.-K.

“…Objective –  Many patients with Parkinson's disease (PD) lose weight also early during the disease. The objective of the study was to investigate possible…”
Get full text

Multiple Sclerosis and Exposure to Solvents, Ionizing Radiation and Animals by Landtblom, A M, Flodin, Ulf, Karlsson, M, Palhagen, S, Axelson, Olav, Soderfeldt, B

“…Earlier studies have indicated an association between multiple sclerosis and environmental factors, especially occupational exposure to solvents. The present…”
Get full text

Oxysterols and Parkinson's disease: Evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease by Björkhem, Ingemar, Lövgren-Sandblom, Anita, Leoni, Valerio, Meaney, Steve, Brodin, Lovisa, Salveson, Lisette, Winge, Kristian, Pålhagen, Sven, Svenningsson, Per

“…•24S-hydroxycholesterol in plasma is not a suitable biomarker for Parkinson's disease.•Levels of 24S-hydroxycholesterol in CSF are correlated to duration of…”
Get full text

Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients by Paul, Gesine, Zachrisson, Olof, Varrone, Andrea, Almqvist, Per, Jerling, Markus, Lind, Göran, Rehncrona, Stig, Linderoth, Bengt, Bjartmarz, Hjalmar, Shafer, Lisa L, Coffey, Robert, Svensson, Mikael, Mercer, Katarina Jansson, Forsberg, Anton, Halldin, Christer, Svenningsson, Per, Widner, Håkan, Frisén, Jonas, Pålhagen, Sven, Haegerstrand, Anders

“…BACKGROUND. Recombinant human PDGF-BB (rhPDGF-BB) reduces Parkinsonian symptoms and increases dopamine transporter (DAT) binding in several animal models of…”
Get full text

Safety and efficacy of recombinant human platelet derived growth factor (Rhpdgf) in Parkinson's disease by Paul, G, Zachrisson, O, Varrone, A, Almqvist, P, Jerling, M, Lindh, G, Rehncrona, S, Linderoth, B, Bjartmarz, H, Svensson, M, Mercer, K. Jansson, Forsberg, A, Shafer, L.L, Lang, A.M. Janson, Halldin, C, Svenningsson, P, Widner, H, Frisen, J, Pålhagen, S, Haegerstrand, A

Get full text